Pouchitis Market 2024-2031: Growth, Trends, and Key Players

Pouchitis Market Size, Share, Industry, Forecast and Outlook (2024-2031)

<h2>Global Pouchitis Market&nbsp;is segmented By Type (Acute Pouchitis, Relapsing Pouchitis, Chronic Pouchitis) By Treatment (Antibiotics, Probiotics, Antidiarrheal Agents, Others) By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others)&nbsp;and By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) &ndash; Share, Size, Outlook, and Opportunity Analysis, 2024-2031</h2>

<h3>Market Overview</h3>

<blockquote>
Global Pouchitis Market reached US$ YY&nbsp;Billion in 2022 and is expected to reach US$ YY&nbsp;Billion by 2031, growing with a CAGR of YY% during the forecast period 2024-2031.
</blockquote>

The global pouchitis market has been experiencing significant growth over the years owing to the increasing prevalence of gastrointestinal diseases and the increase in the surgical procedures of IBD drive market growth. After a patient has had a total proctocolectomy (removal by colon and rectum surgery), an ileal pouch-anal anastomosis (IPAA) is performed, which leads to pouchitis.&nbsp;

Moreover, the increase in product launches and approvals drives the market&rsquo;s growth. The antibiotics segment is dominant in the market share and acts as the first line of medication. The use of nonsteroidal anti-inflammatory drugs (NSAIDs), especially over a long period of time, will develop pouchitis. Alternative antibiotic availability will aid in market growth.&nbsp;&nbsp;

The antibiotics segment accounts for over half of the market share. Similarly, North America dominates the market share by launching and introducing novel products and treatment procedures. The healthcare infrastructure and the improved healthcare in this region hold the region in the dominant position.&nbsp;

<h3>Market Scope</h3>

<table cellspacing="0" style="border-collapse:collapse">
	<tbody>
		<tr>
			<td style="background-color:#4472c4; border-bottom:1px solid #4472c4; border-left:1px solid #4472c4; border-right:1px solid #8eaadb; border-top:1px solid #4472c4; vertical-align:top; width:312px">
			Metrics
			</td>
			<td style="background-color:#4472c4; border-bottom:1px solid #4472c4; border-left:1px solid #8eaadb; border-right:1px solid #4472c4; border-top:1px solid #4472c4; vertical-align:top; width:312px">
			Details
			</td>
		</tr>
		<tr>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #4472c4; vertical-align:middle; width:312px">
			CAGR
			</td>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #4472c4; vertical-align:middle; width:312px">
			YY%
			</td>
		</tr>
		<tr>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Size Available for Years
			</td>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			2022-2031
			</td>
		</tr>
		<tr>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Forecast Period
			</td>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			2024-2031
			</td>
		</tr>
		<tr>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Data Availability
			</td>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Value (US$)&nbsp;
			</td>
		</tr>
		<tr>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Segments Covered
			</td>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Type, Treatment, Distribution channel&nbsp;
			</td>
		</tr>
		<tr>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Regions Covered
			</td>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			North America, Europe, Asia-Pacific, South America, and Middle East &amp; Africa
			</td>
		</tr>
		<tr>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Fastest Growing Region
			</td>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Asia-Pacific
			</td>
		</tr>
		<tr>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Largest Region
			</td>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			North America
			</td>
		</tr>
		<tr>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Report Insights Covered
			</td>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter&rsquo;s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis, and Other key Insights.
			</td>
		</tr>
	</tbody>
</table>

&nbsp;

For more details on this report - <a href="https://www.datamintelligence.com/download-sample/pouchitis-market" target="_blank">Request for Sample</a>

<h3>&nbsp;</h3>

<h3>Market Dynamics</h3>

Prevalence of Inflammatory Bowel Disease is expected to Drive the Market Growth

The prevalence of bowel inflammatory disease is driving the growth of the market. For instance, according to CDC, n estimated 3.1 million adults (1.3%) in the United States have been diagnosed with inflammatory bowel disease (IBD), which includes Crohn&#39;s disease and ulcerative colitis. It is a broad term that indicates chronic inflammation of the gastrointestinal tract. IBD has been associated with poor quality of life and extensive morbidity and often results in complications requiring hospitalizations and surgical procedures.

Pouchitis can frequently develop in patients with IBD after creating an IPAA, significantly impairing quality of life. Additionally, according to NIH, About 10% of patients with IBD who develop pouchitis require pouch excision, and several risk factors of the failure have been reported.

Increase in Ileal Pouch- Anal Anastomosis (IPAA) will Drive the Market Growth

The increase in IPAA surgeries will elevate the market growth. IPAA is preferred for ulcerative colitis. For instance, according to Crohn&rsquo;s and Colitis Foundation, approximately 30% of ulcerative colitis patients require surgery during their disease course. According to NIH, the prevalence of ulcerative colitis is estimated to be 156 to 291 cases per 100,000 persons per year. The preferred and most common surgery is the staged total proctocolectomy with ileal pouch-anal anastomosis (IPAA).&nbsp;

Despite the benefits of intestinal continuity and improved quality of life, IPAA is associated with multiple complications, the most common of which is pouchitis. The total proctocolectomy with ileal pouch&ndash;anal anastomosis (IPAA) is the surgical intervention of choice in subjects affected by ulcerative colitis (UC). Thus, the increase in IPAA surgeries is expected to raise market growth.&nbsp;

Side Effects of the Available Treatment Options can Impede the Market Growth

The side effects of the available treatment options can decline the market growth. The long-term use of antibiotics is ineffective in achieving clinical remission, where treatment is no longer needed to control symptoms. Long-term use of antibiotics for chronic pouchitis is associated with antibiotic-related side effects and the development of antibiotic resistance.&nbsp;

Side effects of antibiotics, development of resistance to antibiotics, and the development of Clostridium. Additionally, Side effects included vomiting, dysgeusia (metallic taste in mouth), or transient peripheral neuropathy (damage to nerves).&nbsp; The symptoms persist despite a course of more than four weeks of antibiotic therapy. Thus, the side effects of the treatment will decline the market growth.&nbsp;

<h3>Segment Analysis</h3>

The global pouchitis market is segmented based on type, treatment, distribution channel and region.

Antibiotics Segment is Expected to hold a Dominant Position in the Market Share

Antibiotics are first-line therapy for acute pouchitis, consisting of an oral antibiotic for two weeks. Pouchitis, often developing after colectomy and ileal pouch-anal anastomosis for ulcerative colitis, is highly responsive to antibiotics. Ciprofloxacin and/or metronidazole are commonly used, often for prolonged periods.

Patients with acute pouchitis are commonly treated with antibiotics, specifically ciprofloxacin and/or metronidazole, for an empiric 2-week course. Many patients may become antibiotic-dependent, and some require long antibiotic courses. Most patients with acute pouchitis have symptomatic improvement (e.g., improved stool frequency, no urgency) within three days of antibiotic therapy. The benefits of antibiotics against pouchitis disease make the antibiotics preferable. Thus, the above factors will drive the segment growth.&nbsp;

<h3>Geographical Penetration</h3>

North America Holds a Significant Position in the Market Share

Increase in the number of product approvals and launches due to the presence of major key players in the region and the improved healthcare system in the region is expected to hold a significant position in the market share. For instance, on November 10, 2022, the Food and Drug Administration (FDA) granted Orphan Drug designation to AMT-101 for treating pouchitis, an inflammation that develops following ileal pouch-anal anastomosis surgery in patients with ulcerative colitis.&nbsp;

Additionally, on December 17, 2021, Takeda Pharmaceutical Company Limited&nbsp; (&ldquo;Takeda&rdquo;) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) had recommended the approval of intravenous (IV) vedolizumab for the treatment of adult patients with moderately to severely active chronic pouchitis, who have undergone proctocolectomy and ileal pouch-anal anastomosis (IPAA) for ulcerative colitis (UC) and have had an inadequate response with or lost response to antibiotic therapy. Thus, the launches and approvals by the companies will drive market growth over the forecast period.&nbsp;

<h3>COVID-19 Impact Analysis</h3>

The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for pharmaceutical markets worldwide, including the global pouchitis market. The supply chains were disrupted due to the lockdowns. The manufacturing processes of the products were interrupted as the companies faced the crisis.&nbsp;

The onset of the pandemic in early 2020 led to widespread lockdowns and restrictions that delayed the diagnosis, treatment procedures, and follow-up checking with the healthcare professional. The prognosis of the disease has experienced severity due to the lack of availability of the medicine.&nbsp;&nbsp;

The COVID-19 pandemic severely disrupted the growth of the markets. The companies experienced unprecedented losses worldwide.&nbsp; The restriction in the supply of non-essential medicine has created a drug crisis. The company&rsquo;s focus has shifted to manufacturing emergency medicine for COVID-19, which was killing a number of people. However, the guidelines and the restrictions aided in stopping the spread of the virus. Thus, COVID-19 have impacted the market.&nbsp;

<h3>Key Developments</h3>

<ul>
	<li>On March 30, 2023, Takeda confirmed that the New England Journal of Medicine (NEJM) had published positive data from the Phase 4 EARNEST study of vedolizumab to treat chronic pouchitis.&nbsp;</li>
	<li>On February 3, 2023, Takeda announced that the European Commission had granted marketing authorization for the intravenous (IV) formulation of vedolizumab for the treatment of adult patients with moderately to severely active chronic pouchitis who have undergone proctocolectomy and ileal pouch-anal anastomosis (IPAA) for ulcerative colitis (UC) and have had an inadequate response with or lost response to antibiotic therapy. Vedolizumab is the first treatment indicated for active chronic pouchitis across the European Union.</li>
</ul>

<h3>Competitive Landscape</h3>

The major global players in the market include Dr. Reddy&#39;s Laboratories, Ravoos Laboratories Ltd., Pfizer, Wellona Pharma, Aden Healthcare, Manus Aktteva Biopharma LLP, Anant Pharmaceuticals Pvt Ltd, Enomark Pharma, Reliance Life Sciences, Atom Pharma among others.

<h3>Why Purchase the Report?</h3>

<ul>
	<li>To visualize the global pouchitis market segmentation based on type, treatment, distribution channel and region as well as understand key commercial assets and players.</li>
	<li>Identify commercial opportunities by analyzing trends and co-development.&nbsp;</li>
	<li>Excel data sheet with numerous data points of pouchitis market-level with all segments.</li>
	<li>PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.</li>
	<li>Product mapping available as excel consisting of key products of all the major players.</li>
</ul>

The global pouchitis market report would provide approximately 61 tables, 58 figures, and 186 Pages.

<h3>Target Audience 2024</h3>

<ul>
	<li>Manufacturers/ Buyers</li>
	<li>Industry Investors/Investment Bankers</li>
	<li>Research Professionals</li>
	<li>Emerging Companies</li>
</ul>

<ol>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Methodology and Scope</h3>

	<ol>
		<li>Research Methodology</li>
		<li>Research Objective and Scope of the Report</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Definition and Overview</h3>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Executive Summary</h3>

	<ol>
		<li>Snippet by Type</li>
		<li>Snippet by Treatment</li>
		<li>Snippet by Distribution Channel</li>
		<li>Snippet by Region</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Dynamics</h3>

	<ol>
		<li>Impacting Factors
		<ol>
			<li>Drivers
			<ol>
				<li>Prevalence of inflammatory bowel disease (IBD)</li>
				<li>Increase in ileal pouch-anal anastomosis (IPAA)&nbsp;</li>
			</ol>
			</li>
			<li>Restraints
			<ol>
				<li>Side effects of the available treatment options&nbsp;</li>
			</ol>
			</li>
			<li>Opportunity</li>
			<li>Impact Analysis</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Industry Analysis&nbsp;</h3>

	<ol>
		<li>Porter&#39;s Five Force Analysis&nbsp;</li>
		<li>Supply Chain Analysis</li>
		<li>Pricing Analysis</li>
		<li>Regulatory Analysis</li>
		<li>Russia-Ukraine War Impact Analysis</li>
		<li>DMI Opinion</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">COVID-19 Analysis</h3>

	<ol>
		<li>Analysis of COVID-19
		<ol>
			<li>Scenario Before COVID</li>
			<li>Scenario During COVID</li>
			<li>Scenario Post COVID</li>
		</ol>
		</li>
		<li>Pricing Dynamics Amid COVID-19</li>
		<li>Demand-Supply Spectrum</li>
		<li>Government Initiatives Related to the Market During the Pandemic</li>
		<li>Manufacturers Strategic Initiatives</li>
		<li>Conclusion</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">By Type</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Attractiveness Index, By Type</li>
		</ol>
		</li>
		<li>Portland*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%)</li>
		</ol>
		</li>
		<li>Blended</li>
		<li>Others</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">By Treatment</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment</li>
			<li>Market Attractiveness Index, By Treatment</li>
		</ol>
		</li>
		<li>Antibiotics*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%)</li>
		</ol>
		</li>
		<li>Probiotics</li>
		<li>Antidiarrheal Agents</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">By Distribution Channel</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Attractiveness Index, By Distribution Channel</li>
		</ol>
		</li>
		<li>Hospital Pharmacy*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%)</li>
		</ol>
		</li>
		<li>Retail Pharmacy</li>
		<li>Others</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">By Region</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Region</li>
			<li>Market Attractiveness Index, By Region</li>
		</ol>
		</li>
		<li>North America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution channel</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>U.S.</li>
				<li>Canada</li>
				<li>Mexico</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Europe
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution channel</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>Germany</li>
				<li>UK</li>
				<li>France</li>
				<li>Italy</li>
				<li>Spain</li>
				<li>Rest of Europe</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>South America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution channel</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>Brazil</li>
				<li>Argentina</li>
				<li>Rest of South America</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Asia-Pacific
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution channel</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>China</li>
				<li>India</li>
				<li>Japan</li>
				<li>South Korea</li>
				<li>Rest of Asia-Pacific</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Middle East and Africa
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution channel</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Competitive Landscape</h3>

	<ol>
		<li>Competitive Scenario</li>
		<li>Market Positioning/Share Analysis</li>
		<li>Mergers and Acquisitions Analysis</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Company Profiles</h3>

	<ol>
		<li>Dr. Reddy&#39;s Laboratories*
		<ol>
			<li>Company Overview</li>
			<li>Product Portfolio and Description</li>
			<li>Financial Overview</li>
			<li>Key Developments</li>
		</ol>
		</li>
		<li>Ravoos Laboratories Ltd.&nbsp;</li>
		<li>Pfizer&nbsp;</li>
		<li>Wellona Pharma&nbsp;</li>
		<li>Aden Healthcare&nbsp;</li>
		<li>Manus Aktteva Biopharma LLP&nbsp;</li>
		<li>Anant Pharmaceuticals Pvt Ltd</li>
		<li>Enomark Pharma</li>
		<li>Reliance Life Sciences&nbsp;</li>
		<li>Atom Pharma&nbsp;(LIST NOT EXHAUSTIVE)&nbsp;</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Appendix</h3>

	<ol>
		<li>About Us and Services</li>
		<li>Contact Us</li>
	</ol>
	</li>
</ol>

List of Tables

Table 1 Global Pouchitis Market Value, By Type, 2023, 2027 &amp; 2031 (US$ Million)

Table 2 Global Pouchitis Market Value, By Treatment, 2023, 2027 &amp; 2031 (US$ Million)

Table 3 Global Pouchitis Market Value, By Distribution Channel, 2023, 2027 &amp; 2031 (US$ Million)

Table 4 Global Pouchitis Market Value, By Region, 2023, 2027 &amp; 2031 (US$ Million)

Table 5 Global Pouchitis Market Value, By Type, 2023, 2027 &amp; 2031 (US$ Million)

Table 6 Global Pouchitis Market Value, By Type, 2022-2031 (US$ Million)

Table 7 Global Pouchitis Market Value, By Treatment, 2023, 2027 &amp; 2031 (US$ Million)

Table 8 Global Pouchitis Market Value, By Treatment, 2022-2031 (US$ Million)

Table 9 Global Pouchitis Market Value, By Distribution Channel, 2023, 2027 &amp; 2031 (US$ Million)

Table 10 Global Pouchitis Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 11 Global Pouchitis Market Value, By Region, 2023, 2027 &amp; 2031 (US$ Million)

Table 12 Global Pouchitis Market Value, By Region, 2022-2031 (US$ Million)

Table 13 North America Pouchitis Market Value, By Type, 2022-2031 (US$ Million)

Table 14 North America Pouchitis Market Value, By Treatment, 2022-2031 (US$ Million)

Table 15 North America Pouchitis Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 16 North America Pouchitis Market Value, By Country, 2022-2031 (US$ Million)

Table 17 South America Pouchitis Market Value, By Type, 2022-2031 (US$ Million)

Table 18 South America Pouchitis Market Value, By Treatment, 2022-2031 (US$ Million)

Table 19 South America Pouchitis Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 20 South America Pouchitis Market Value, By Country, 2022-2031 (US$ Million)

Table 21 Europe Pouchitis Market Value, By Type, 2022-2031 (US$ Million)

Table 22 Europe Pouchitis Market Value, By Treatment, 2022-2031 (US$ Million)

Table 23 Europe Pouchitis Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 24 Europe Pouchitis Market Value, By Country, 2022-2031 (US$ Million)

Table 25 Asia-Pacific Pouchitis Market Value, By Type, 2022-2031 (US$ Million)

Table 26 Asia-Pacific Pouchitis Market Value, By Treatment, 2022-2031 (US$ Million)

Table 27 Asia-Pacific Pouchitis Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 28 Asia-Pacific Pouchitis Market Value, By Country, 2022-2031 (US$ Million)

Table 29 Middle East &amp; Africa Pouchitis Market Value, By Type, 2022-2031 (US$ Million)

Table 30 Middle East &amp; Africa Pouchitis Market Value, By Treatment, 2022-2031 (US$ Million)

Table 31 Middle East &amp; Africa Pouchitis Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 32 Dr. Reddy&#39;s Laboratories: Overview

Table 33 Dr. Reddy&#39;s Laboratories: Product Portfolio

Table 34 Dr. Reddy&#39;s Laboratories: Key Developments

Table 35 Ravoos Laboratories Ltd.: Overview

Table 36 Ravoos Laboratories Ltd.: Product Portfolio

Table 37 Ravoos Laboratories Ltd.: Key Developments

Table 38 Pfizer: Overview

Table 39 Pfizer: Product Portfolio

Table 40 Pfizer: Key Developments

Table 41 Wellona Pharma: Overview

Table 42 Wellona Pharma: Product Portfolio

Table 43 Wellona Pharma: Key Developments

Table 44 Aden Healthcare: Overview

Table 45 Aden Healthcare: Product Portfolio

Table 46 Aden Healthcare: Key Developments

Table 47 Manus Aktteva Biopharma LLP: Overview

Table 48 Manus Aktteva Biopharma LLP: Product Portfolio

Table 49 Manus Aktteva Biopharma LLP: Key Developments

Table 50 Anant Pharmaceuticals Pvt Ltd: Overview

Table 51 Anant Pharmaceuticals Pvt Ltd: Product Portfolio

Table 52 Anant Pharmaceuticals Pvt Ltd: Key Developments

Table 53 Enomark Pharma: Overview

Table 54 Enomark Pharma: Product Portfolio

Table 55 Enomark Pharma: Key Developments

Table 56 Reliance Life Sciences: Overview

Table 57 Reliance Life Sciences: Product Portfolio

Table 58 Reliance Life Sciences: Key Developments

Table 59 Atom Pharma: Overview

Table 60 Atom Pharma: Product Portfolio

Table 61 Atom Pharma: Key Developments

List of Figures

Figure 1 Global Pouchitis Market Value, 2022-2031 (US$ Million)

Figure 2 Global Pouchitis Market Share, By Type, 2023 &amp; 2031 (%)

Figure 3 Global Pouchitis Market Share, By Treatment, 2023 &amp; 2031 (%)

Figure 4 Global Pouchitis Market Share, By Distribution Channel, 2023 &amp; 2031 (%)

Figure 5 Global Pouchitis Market Share, By Region, 2023 &amp; 2031 (%)

Figure 6 Global Pouchitis Market Y-o-Y Growth, By Type, 2023-2031 (%)

Figure 7 Portland Pouchitis Market Value, 2022-2031 (US$ Million)

Figure 8 Others Pouchitis Market Value, 2022-2031 (US$ Million)

Figure 9 Others Pouchitis Market Value, 2022-2031 (US$ Million)

Figure 10 Global Pouchitis Market Y-o-Y Growth, By Treatment, 2023-2031 (%)

Figure 11 Antibiotics Treatment in Global Pouchitis Market Value, 2022-2031 (US$ Million)

Figure 12 Probiotics Treatment in Global Pouchitis Market Value, 2022-2031 (US$ Million)

Figure 13 Antidiarrheal Agents Treatment in Global Pouchitis Market Value, 2022-2031 (US$ Million)

Figure 14 Global Pouchitis Market Y-o-Y Growth, By Distribution Channel, 2023-2031 (%)

Figure 15 Hospital Pharmacy Distribution Channel in Global Pouchitis Market Value, 2022-2031 (US$ Million)

Figure 16 Retail Pharmacy Distribution Channel in Global Pouchitis Market Value, 2022-2031 (US$ Million)

Figure 17 Others Distribution Channel in Global Pouchitis Market Value, 2022-2031 (US$ Million)

Figure 18 Global Pouchitis Market Y-o-Y Growth, By Region, 2023-2031 (%)

Figure 19 North America Pouchitis Market Value, 2022-2031 (US$ Million)

Figure 20 Asia-Pacific Pouchitis Market Value, 2022-2031 (US$ Million)

Figure 21 Europe Pouchitis Market Value, 2022-2031 (US$ Million)

Figure 22 South America Pouchitis Market Value, 2022-2031 (US$ Million)

Figure 23 Middle East and Africa Pouchitis Market Value, 2022-2031 (US$ Million)

Figure 24 North America Pouchitis Market Value, 2022-2031 (US$ Million)

Figure 25 North America Pouchitis Market Share, By Type, 2023 &amp; 2031 (%)

Figure 26 North America Pouchitis Market Share, By Treatment, 2023 &amp; 2031 (%)

Figure 27 North America Pouchitis Market Share, By Distribution Channel, 2023 &amp; 2031 (%)

Figure 28 North America Pouchitis Market Share, By Country, 2023 &amp; 2031 (%)

Figure 29 South America Pouchitis Market Value, 2022-2031 (US$ Million)

Figure 30 South America Pouchitis Market Share, By Type, 2023 &amp; 2031 (%)

Figure 31 South America Pouchitis Market Share, By Treatment, 2023 &amp; 2031 (%)

Figure 32 South America Pouchitis Market Share, By Distribution Channel, 2023 &amp; 2031 (%)

Figure 33 South America Pouchitis Market Share, By Country, 2023 &amp; 2031 (%)

Figure 34 Europe Pouchitis Market Value, 2022-2031 (US$ Million)

Figure 35 Europe Pouchitis Market Share, By Type, 2023 &amp; 2031 (%)

Figure 36 Europe Pouchitis Market Share, By Treatment, 2023 &amp; 2031 (%)

Figure 37 Europe Pouchitis Market Share, By Distribution Channel, 2023 &amp; 2031 (%)

Figure 38 Europe Pouchitis Market Share, By Country, 2023 &amp; 2031 (%)

Figure 39 Asia-Pacific Pouchitis Market Value, 2022-2031 (US$ Million)

Figure 40 Asia-Pacific Pouchitis Market Share, By Type, 2023 &amp; 2031 (%)

Figure 41 Asia-Pacific Pouchitis Market Share, By Treatment, 2023 &amp; 2031 (%)

Figure 42 Asia-Pacific Pouchitis Market Share, By Distribution Channel, 2023 &amp; 2031 (%)

Figure 43 Asia-Pacific Pouchitis Market Share, By Country, 2023 &amp; 2031 (%)

Figure 44 Middle East &amp; Africa Pouchitis Market Value, 2022-2031 (US$ Million)

Figure 45 Middle East &amp; Africa Pouchitis Market Share, By Type, 2023 &amp; 2031 (%)

Figure 46 Middle East &amp; Africa Pouchitis Market Share, By Treatment, 2023 &amp; 2031 (%)

Figure 47 Middle East &amp; Africa Pouchitis Market Share, By Distribution Channel, 2023 &amp; 2031 (%)

Figure 48 Dr. Reddy&#39;s Laboratories: Financials

Figure 49 Ravoos Laboratories Ltd.: Financials

Figure 50 Pfizer: Financials

Figure 51 Wellona Pharma: Financials

Figure 52 Aden Healthcare: Financials

Figure 53 Manus Aktteva Biopharma LLP: Financials

Figure 54 Anant Pharmaceuticals Pvt Ltd: Financials

Figure 55 Enomark Pharma: Financials

Figure 56 Reliance Life Sciences: Financials

Figure 57 Atom Pharma: Financials

Pouchitis Market Size, Share, Industry, Forecast and Outlook (2024-2031)

Bacterial Infectious Diseases Therapeutics Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: 2024 July 09

Starting from

Inflammatory Bowel Disease Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: 2024 June 25

Starting from

Ulcerative Colitis Treatment Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: 2024 February 23

Starting from